The worldwide prevalence of infection with human papillomavirus (HPV) in women without
cervical abnormalities is 11–12% with higher rates in sub-Saharan Africa (24%), Eastern …

Abstract Background Anogenital warts (AGWs) are a common, highly infectious disease
caused by the human papillomavirus (HPV), whose high recurrence rates contribute to direct …

Background Quadrivalent human papillomavirus (HPV) vaccine has high efficacy in clinical
trials but no reports describe its effects at a population level. From July, 2007, Australia was …

Background Evidence-based priority setting is increasingly important for rationally
distributing scarce health resources and for guiding future health research. We sought to …

Background: Sexually transmitted infection with the human papillomavirus (HPV) is
responsible for a significant burden of human cancers involving the cervix, anogenital tract …

Abstract Objectives/Hypothesis: To develop a national database of cases of juvenile onset
recurrent respiratory papillomatosis (JoRRP) in Canada, to calculate trends in incidence and …

Randomized clinical trials are currently examining the efficacy of a nonavalent human
papillomavirus (HPV) vaccine, including HPV‐types 6/11/16/18/31/33/45/52/58. Evidence on …

Background: The burden of anogenital warts will be a determining factor when making
decisions about the type of human papillomavirus (HPV) vaccine to be used (bivalent or …

Background Recent evidence suggests that two doses of HPV vaccines may be as
protective as three doses in the short-term. We estimated the incremental cost-effectiveness …

Background Human papilloma virus (HPV) types 6 and 11 account for 90 percent of
anogenital warts (AGW). Assessment of a potential reduction of the incidence of AGW …